In the Zone: old vs new technologies

Investing in new technologies in the field of bioanalysis has its obvious advantages. New technologies often offer improved data quality and accuracy; better efficiency cutting costs and time of analysis; and ethical solutions in the reduction of animals required for testing.

However, there are key obstacles in the implementation of new technologies, such as financial and regulatory constraints, which could encourage decision makers to stay with older, outdated or more traditional analytical methodologies.

In this feature, we will be looking at the evolution of technologies over the last century, focusing on the developments and advancements in large molecule analysis.

Throughout the feature, we will be investigating the pros and cons of utilizing the different technologies available for large molecule analysis, and will consult with experts to answer the key questions involved when choosing a technology for analytical research.



Addressing the key challenges and questions when deciding between old vs new technologies: a podcast with Franklin Spriggs (KCAS)

Franklin SpriggsAs part of our focus, In the Zone: old vs new technologies, we present this podcast where we talk to Franklin Spriggs (Director of Large Molecule Services, KCAS) about his experience with investing in different technologies, and the key questions that need to be addressed when making any decision between different technologies.



Top 5 techniques and tips for choosing old vs new technologies

Learn more about the pros and cons of investing in new technologies or sticking with more traditional techniques, as well as about the key questions that should be considered before making the decision. In this infographic, we investigate the pros and cons of utilizing four different technologies available for large molecule analysis: colorimetric ELISA, Meso-Scale Diagnostics, Time Resolved Fluorescence and Quanterix Simoa.




1 Oligonucleotide pharmacokinetic/drug metabolism bioanalysis via hybridization ELISA

2 Current thinking on quantification of protein therapeutic pharmacokinetics and protein biomarkers in clinical studies